Article Information
PubMed
Published By
Online ISSN
History
- Received September 29, 2022
- Revision received April 14, 2023
- Accepted April 17, 2023
- Published online April 25, 2023.
Copyright & Usage
© 2023 Takada et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
Author Information
- Yoko K Takada1, Data curation,
- Scott I Simon1,2, Resources, Writing—review and editing and
- Yoshikazu Takada1,3, Conceptualization, Formal analysis, Funding acquisition, Project administration⇑
- 1Department of Dermatology, UC Davis School of Medicine, Sacramento, CA, USA
- 2Department of Biomedical Engineering, UC Davis, Davis, CA, USA
- 3Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA
- Correspondence: ytakada{at}ucdavis.edu
Funding
NCI
NCI P30CA093373UC | UCD | Comprehensive Cancer Center, University of California, Davis (UC Davis Comprehensive Cancer Center)
Pilot fundingY TakadaNational Cancer Institute
R01 AI407294SI Simon
In this Issue
Advertisement
Subjects
Related Articles
Cited By...
- FGF2 binds to the allosteric site (site 2) and activates {alpha}v{beta}3 integrin and FGF1 binds to site 2 but suppresses integrin activation by FGF2: a potential mechanism of anti-inflammatory action of FGF1
- FGF2 binds to the allosteric site (site 2) and activates integrin {alpha}IIb{beta}3 and FGF1 binds to site 2 but suppresses integrin activation by FGF2: A potential mechanism of anti-thrombotic action of FGF1